Cepacol Extra Strength Cherry

Quick links to important sections

Cepacol Extra Strength Cherry

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cepacol Extra Strength Cherry

Property Description
Active Ingredient(s) Benzocaine, Menthol
Form Oral Lozenge
Pharmacological Class Local Anesthetic, Oral Pain Reliever
Common Use Temporary symptomatic pain relief
Origin Synthetic (Benzocaine), Derived (Menthol)

What Type of Medicine is Cepacol Extra Strength Cherry?

Cepacol Extra Strength Cherry is an established Over-the-counter (OTC) medicine presented as an oral lozenge and is medically categorized as a Local Anesthetic and Oral Pain Reliever. This pharmaceutical preparation is uniquely formulated for oromucosal/topical administration, meaning its primary therapeutic effect is concentrated directly on the lining of the mouth and throat. The lozenge format facilitates sustained contact between the active ingredients and the painful area as it dissolves slowly. An analysis of the Benzocaine compound, the primary active ingredient in this formulation, confirms its established role as a local anesthetic agent utilized for pain relief from minor irritation.


Core Ingredients and Composition

The lozenge is a combination product containing two primary active ingredients: Benzocaine and Menthol. Benzocaine is a synthetic compound classified as an Ester Local Anesthetic, recognized for its rapid Maximum Numbing capability. Menthol, which is often naturally derived, complements this action as a secondary oral analgesic and cooling agent. Benzocaine is a recognized active substance for temporary pain relief in the mouth and throat. The Extra Strength formulation, defined by its higher concentration of the anesthetic component than standard varieties, is supported by pharmacological studies confirming its capacity to interrupt localized pain signals.


What is the General Purpose of This Topical Anesthetic?

The general purpose of this topical anesthetic is to provide fast-acting, temporary symptomatic relief from localized pain and irritation in the mouth and throat—a typical scenario being throat discomfort. The established mechanism relies on the numbing action of Benzocaine, which works by chemically interrupting the nerve signals that transmit pain, combined with the surface cooling effect of Menthol. This dual-component approach is clinically recognized for its efficacy in rendering the affected tissues temporarily insensitive to painful stimuli, serving as an effective, short-term measure to mitigate acute discomfort.

What side effects are possible with Cepacol Extra Strength Cherry?

Possible side effects and safety information

The safety profile of the Cepacol Extra Strength Cherry lozenge is defined primarily by the properties of its active local anesthetic ingredient, Benzocaine, as documented by government regulatory bodies.


Documented Adverse Reactions

The most significant and serious adverse reaction associated with Benzocaine is Methemoglobinemia, which is classified as rare but clinically important in regulatory documents, including warnings issued by the FDA. This condition affects the Blood and Lymphatic System by impairing the blood's capacity to transport oxygen. The onset of this serious condition has been documented to occur within minutes to hours after topical use.

Other adverse reactions are grouped within the following System-Organ Classes:

  • Immune System Disorders: Potential for hypersensitivity or allergic reactions to the active ingredients or related anesthetic compounds.
  • General Disorders and Administration Site Conditions: Expected local irritation, such as a transient stinging or burning sensation at the application site.

Population-Specific and Use Restrictions

Specific safety considerations are noted for certain populations and usage constraints are documented in the official labeling:

  • Pediatric Safety: Use is explicitly discouraged or restricted in the pediatric population, particularly children under 2 years of age, due to the heightened risk of Methemoglobinemia.
  • Cardiopulmonary Risk: Individuals with pre-existing conditions such as asthma, heart disease, or chronic lung issues are noted to be potentially at greater risk for Methemoglobinemia.
  • Allergy Constraint: The product is restricted for use in individuals with a known history of hypersensitivity to Benzocaine or other ester-type local anesthetics.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for this product is centered on the risk of systemic toxicity associated with the Benzocaine component. Overdose may present as Methemoglobinemia, a serious, potentially fatal condition where the blood's oxygen-carrying capacity is severely reduced.

Documented Manifestations and Actions

Overdose manifestations officially documented include signs of reduced blood oxygen, such as the development of a pale, gray, or blue discoloration of the skin, lips, or nail beds (cyanosis). Other systemic symptoms include severe headache, rapid heart rate (tachycardia), dizziness, fatigue, and confusion.

If any of these symptoms develop, the regulatory instruction is to stop use and seek immediate medical attention. In the event that an amount larger than used for pain is accidentally swallowed, a Poison Control Center must be contacted right away.

Severe Outcomes and Specific Risks

Documented severe outcomes include the potential for Central Nervous System effects, such as seizures or coma, with the most severe cases of Methemoglobinemia having resulted in death.

Individuals with specific underlying conditions, including breathing problems (like asthma or emphysema) or G6PD deficiency, are noted in official labeling as having a potentially greater risk for complications. The emergency treatment for severe toxicity is supportive and may involve the administration of Methylene blue.

Therapeutic Uses of Cepacol Extra Strength Cherry

The primary therapeutic use of this lozenge is to provide temporary and localized symptomatic relief, focused on symptoms related to physical discomfort in the oropharyngeal area. The lozenge is used to help manage the symptom clusters of occasional minor irritation, pain, sore mouth, and sore throat, alongside discomfort associated with canker sores. This preparation is commonly used in conditions characterized by periods of heightened symptoms of pain and soreness in the throat and mouth.

The Extra Strength formulation contributes to easing the overall symptom burden by delivering focused symptomatic relief. This supportive relief assists with maintaining functional stability by temporarily reducing the intensity of pain that interferes with routine activities like speaking and swallowing.

“This preparation is relevant when supportive symptom management is appropriate, particularly during acute or disruptive episodes linked to the common cold or flu.”

Applied in phases of increased discomfort, it helps the patient cope more steadily by offering supportive, short-term symptomatic assistance while the symptoms of irritation are present.


Quick Fact: Relief for Acute Localized Discomfort

The formulation provides supportive relief when short-term symptomatic assistance is needed to address acute pain or soreness, supporting general well-being during symptomatic phases.


Regulatory References

  1. NIH DailyMed Drug Label Information

Eligibility and Restrictions for Use

Official Eligibility Rules for Cepacol Extra Strength Cherry

The eligibility status for the use of Cepacol Extra Strength Cherry lozenges is strictly defined by official regulatory guidelines, focusing on age, known allergies, and specific underlying health conditions.

Absolute Contraindications (Do Not Use)

Population/Condition Regulatory Requirement
Children under 5 years of age Prohibited from use.
Infants/Children for Teething Strictly contraindicated for treating teething pain.
Allergy to Benzocaine Individuals with a history of hypersensitivity to benzocaine or other 'caine'-type local anesthetics.

Conditional Use Restrictions (Consult a Health Professional)

Population/Condition Regulatory Requirement
Pregnant or Breast-feeding Mandatory consultation with a health professional before use.
Heart or Lung Problems Requires consultation due to increased risk of methemoglobinemia.
Hereditary Metabolic Disorders Requires consultation before use.

Age-Related Eligibility: The lozenge is approved for use in adults and children 5 years of age and older under standard labeled conditions. Individuals in conditional use categories, such as older adults or those with specific comorbidities, must seek professional guidance before beginning treatment.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official interaction profile for this combination product (which contains Benzocaine and, in some formulations, Dextromethorphan HBr) is structured around specific high-risk restrictions and drug-drug combinations documented in regulatory labeling.


Regulatory Interaction Constraints

Component Interacting Medicine or Class Interaction Constraint or Risk
Dextromethorphan Monoamine Oxidase Inhibitors (MAOIs) Do not use with MAOIs or for 2 weeks after stopping MAOI therapy. This restriction is due to the risk of serotonin syndrome (a potentially severe condition).
Dextromethorphan Other Serotonergic Drugs (e.g., SSRIs) Increased risk of serotonin syndrome. Advise consultation with a health professional.
Dextromethorphan Strong CYP2D6 Inhibitors Increased Dextromethorphan exposure and effects.
Dextromethorphan CNS Depressants Increased CNS depressant effects (e.g., sedation).
Benzocaine Local Anesthetics Do not use if allergic to any 'caine' anesthetics (e.g., procaine, butacaine).
Benzocaine Oxidizing Agents (e.g., Dapsone, Nitrates) Increased risk of methemoglobinemia, a potentially serious blood disorder.

Overall Interaction Summary

The primary mandatory restriction is the absolute prohibition of concurrent use with MAOIs, which carries a critical 14-day washout period after the MAOI is discontinued. This restriction is classified as a clinically significant interaction. Official regulatory documents also require patients with a history of allergy to local anesthetics to avoid the product to prevent hypersensitivity. Furthermore, the combination with oxidizing agents and other serotonergic drugs warrants medical consultation due to elevated risks of methemoglobinemia and serotonin syndrome, respectively.

Mechanism of Action

How Cepacol Extra Strength Cherry Works

Cepacol Extra Strength Cherry contains two active ingredients that exert localized effects on peripheral sensory signaling through distinct pharmacodynamic pathways. The primary mechanism involves Benzocaine, which operates as a local anesthetic by physically interacting with voltage-gated sodium channels in the membranes of sensory neurons. Benzocaine stabilizes these channels, thereby inhibiting the essential sodium ion influx required for generating and propagating an action potential (electrochemical signal). This process immediately and reversibly interrupts the nerve signal transduction cascade, resulting in a modified sensory response profile at the application site.

The secondary mechanism involves Menthol, which modulates sensory perception by interacting with the Transient Receptor Potential Melastatin 8 (TRPM8) receptor. Menthol acts as a chemical agonist for this specific cation channel on nerve endings, triggering its activation. This engagement of the chemesthetic signaling pathway initiates a temperature-sensitive signal, thereby altering the local sensory environment.

Dosage and Administration Information

How to Use Cepacol Extra Strength Cherry

The administration of the Cepacol Extra Strength Cherry lozenge is governed by standard instructions defining the pattern for its short-term use. This oral preparation is designed for oromucosal topical administration, meaning the active ingredients are applied directly to the lining of the mouth and throat as the lozenge dissolves slowly.

Official Usage Protocols

The standard adult regimen defines the single unit dose and the frequency of use.

Feature Official Instruction / Detail
Route of Administration Oral route for local topical application.
Standard Dosing One (1) lozenge per dose.
Dosing Frequency May be repeated every two hours as needed.
Administration Method Lozenge must be allowed to dissolve slowly in the mouth; it must not be chewed or swallowed whole.

Duration and Population Constraints

Specific instructions establish limits on the use duration and the patient population. The lozenge is intended for short-term symptomatic management only. Its use must not exceed seven consecutive days; if the underlying condition persists beyond this period, professional medical guidance is necessary.

The preparation is approved for use in Adults and Children 5 years of age and older. The labeling states that the lozenge must not be used in the pediatric population below the age of five years.

Recent Clinical Evidence

Research evidence / Overview of studies for Cepacol Extra Strength Cherry

The research base for the active ingredients in Cepacol Extra Strength Cherry lozenges—Benzocaine and Menthol—focuses on their use for temporary, localized symptomatic change. This overview summarizes the structure of the evidence as described in authoritative regulatory and scientific sources, detailing what the studies explored without offering clinical guidance or claims of efficacy.


Evidence for Temporary Relief of Acute Sore Throat Pain

Research exploring the effects of this type of topical symptomatic change primarily consists of short-term, randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over a brief time period, often comparing the active lozenge to a non-active placebo. Studies were conducted during periods of increased symptom activity in patients with acute, uncomplicated sore throat discomfort.

The research examined outcomes related to physical discomfort, with a specific focus on patient-reported outcomes describing perceived discomfort. Scientists monitored how much the pain intensity scores changed and monitored the reported time interval until the start of perceived symptom change. Findings describe patterns observed in the studies regarding the quickness and short duration of the numbing sensation. The evidence contributes to understanding symptom patterns, particularly concerning conditions associated with acute or disruptive episodes where symptoms may vary in intensity.


Evidence for Relief of Minor Mouth and Throat Irritation

Research supporting the study of the lozenge for minor irritation comes from the established properties of its active ingredient, Benzocaine, which is a recognized active substance for topical anesthetic use. The research base includes data compiled in authoritative regulatory monographs for over-the-counter products intended for temporary, localized discomfort.

These regulatory reviews examine the general capacity of the compound to produce a localized sensory numbing on the oral lining. This evidence is relevant in trials assessing short-term or episodic symptom patterns for minor, localized discomfort. Findings help contextualize how patients reported their experience when dealing with conditions characterized by fluctuating or episodic manifestations of minor soreness. The research describes that the lozenge was studied to examine temporary effects when symptoms become more noticeable.


Gaps in Research and Areas of Uncertainty

This product's research focus is strictly on symptomatic relief, meaning the evidence does not determine whether the use of the lozenge influences the underlying infection or disease progression. One key research limitation is that comparative evidence is lacking in terms of formal, head-to-head trials against all other systemic or topical analgesic classes beyond comparisons to placebo. Also, the follow-up durations were limited in many studies, meaning that while researchers have insight into short-term changes, the long-term effects of using the lozenge repeatedly are not fully established.

Key Studies & References

  1. NIH DailyMed Drug Label Information for Cepacol (Benzocaine/Menthol)
  2. MedlinePlus Drug Information: Benzocaine (Topical)

Frequently Asked Questions (FAQ)

Common questions about Cepacol Extra Strength Cherry (FAQ)

Q: What are the most common reported minor side effects?

Regulatory information indicates that temporary side effects can include a transient numbness or tingling sensation in the mouth and throat, which is related to the product’s intended numbing action. Expected local irritation, such as a slight stinging or burning sensation at the application site, is also noted in official product information.

Q: Is it common to feel a slight irritation or burning sensation when first using the lozenge?

Official safety information describes a transient stinging or burning sensation as an expected local irritation at the site of administration. This is a documented reaction to the anesthetic component as it begins to work.

Q: Are there any warnings regarding driving or operating machinery after using it?

The active ingredients, Benzocaine and Menthol, are not typically associated with effects that impair driving. However, if this product is used alongside other medicines that contain central nervous system (CNS) depressants, there is a possibility that effects like dizziness or drowsiness could be increased. The official labeling for the Benzocaine/Menthol lozenge does not contain a specific driving warning.

Q: Is there any information about using this product with certain medical conditions like diabetes?

Some versions of the lozenge contain inactive ingredients such as sucrose (sugar) and corn syrup. Official labeling indicates that individuals with conditions such as diabetes may need to consult a health professional before use to review the ingredient list.

Q: What official warnings are there about persistent or worsening throat pain while using the lozenge?

Official warnings state that the lozenge should be discontinued if the sore mouth or throat symptoms do not improve within seven days. Additionally, a health professional should be consulted if irritation, pain, or redness persists or worsens, or if swelling develops while using the lozenge.

Q: Can Cepacol Extra Strength Cherry be used for dry coughs?

The documented uses for the Benzocaine and Menthol combination are for the temporary relief of minor irritation, pain, sore throat, and sore mouth. The indications for the Benzocaine and Menthol combination do not typically include the relief of dry cough.

Q: Is this product suitable for sore throat pain caused by allergies?

The product’s documented purpose is to provide temporary symptomatic relief of pain and irritation. The official regulatory scope focuses on the pain symptom itself, and does not differentiate based on the underlying cause (such as allergies).

Q: How long does the numbing or soothing feeling from one lozenge typically last?

Official product instructions define the dosing frequency as 'may be repeated every two hours as needed.' This frequency represents the time interval defined in the official instructions for repeating the dose.

Q: Is Cepacol Extra Strength Cherry available in any non-cherry flavors?

The official product labeling is specific to the 'Cherry' flavor version, which contains coloring ingredients associated with that variety. Other flavors are generally listed as separate drug products with their own distinct labeling.

Q: What is the difference between Cepacol Extra Strength and regular Cepacol lozenges?

The designation 'Extra Strength' in the product name relates to a higher concentration of the local anesthetic ingredient, Benzocaine, compared to standard formulations within the same product line.

Q: Does Cepacol Extra Strength Cherry have any sugar content?

The inactive ingredients listed for the standard cherry flavor formulation include Sucrose (sugar) and Corn Syrup. Versions of the lozenge that are sugar-free are generally labeled as separate products.

Q: Are there different versions of this product, like sugar-free or dye-free?

The standard cherry flavor contains sucrose and artificial colors. Versions that do not contain these specific inactive ingredients are sold as separate products with distinct official labeling.

Q: Can Cepacol Extra Strength Cherry cause any temporary numbness in the mouth or tongue?

As the product’s active ingredient, Benzocaine, is a local anesthetic intended to numb the throat area, the temporary numbing sensation may also be felt in the immediate area, including the mouth and tongue, as the lozenge dissolves.

Q: Does this lozenge contain menthol or other ingredients that cause a cooling sensation?

Yes, the product contains Menthol as a second active ingredient alongside Benzocaine. Menthol is noted in its mechanism of action to provide a soothing and cooling sensation to further alleviate discomfort.

Q: Can the active ingredients affect the sense of taste temporarily?

Since the product's function is to produce temporary numbness (anesthesia) in the oral lining, an effect on local sensory perception, including the sense of taste, may be present while the anesthetic effect lasts.

Q: Is there a risk of interaction if used with common cold and flu medicines?

Official information includes warnings regarding the use of this product with cold and flu medicines that contain oxidizing agents. Combining products that can induce methemoglobinemia (a rare blood disorder) may increase the risk of this serious condition.

Q: Are there interactions to be aware of if taking prescription blood pressure medication?

Official eligibility rules advise consultation with a health professional for individuals with existing conditions such as heart disease. This is primarily due to the potential increased risk of a rare blood disorder called methemoglobinemia in those with pre-existing heart or cardiovascular issues.

Q: Is it typically suitable for use by older adults or seniors?

The lozenge is approved for use in all adults 5 years and older. However, regulatory documents note that the risk of the serious condition methemoglobinemia is potentially higher in older adults who have pre-existing heart or breathing problems. Consultation with a health professional may be necessary in these situations.

Q: Is it okay to use this product if I have a condition like high blood pressure?

Official eligibility rules require consultation with a health professional if an individual has underlying heart disease. Because high blood pressure (hypertension) is a condition that affects the cardiovascular system, professional guidance may be necessary before beginning use.

Q: Why do people sometimes recommend using the lozenge before eating or drinking?

Though not an official instruction, the anesthetic effect can cause temporary numbness in the mouth and throat. Official safety documents advise caution to avoid injury to the numb area (such as accidentally biting the cheek or tongue) while the anesthetic effect is present. This temporary numbness in the throat area may affect the ability to swallow normally.

Q: Does the active ingredient, Hexylresorcinol, have other uses besides numbing the throat?

The active ingredient in this formulation is Benzocaine, not Hexylresorcinol. Official labeling confirms that Benzocaine is classified as a local anesthetic used for the temporary relief of minor mouth and throat pain.

Q: What should a person look for in terms of signs that the product is working?

The product is intended to provide temporary relief through a numbing effect. The primary sign the product is working is the onset of a modified sensory response profile at the application site, resulting in a reduction or numbing of the pain and irritation.

Q: Are there any reports of the lozenge causing stomach upset?

Stomach upset is not listed as a common side effect during normal use. However, regulatory information regarding over-use (overdose) of the active ingredient mentions potential stomach-related side effects, such as nausea, vomiting, and stomach pain.

Q: Can Cepacol Extra Strength Cherry be used for pain in the voice box (larynx)?

The product is formulated for oromucosal topical administration to numb the lining of the mouth and throat. Its effect is localized to the area it contacts and is indicated for relief of minor pain and irritation in those specific areas.

Q: What should be done if the throat irritation is accompanied by a fever?

Official warnings state that if a sore throat is severe, persists for more than two days, or is accompanied or followed by fever, headache, rash, swelling, nausea, or vomiting, consultation with a doctor is necessary.

Q: Are there components in the lozenge that could trigger allergic reactions?

Yes, an allergy alert is mandated for the active ingredient Benzocaine and other 'caine' anesthetics. Additionally, the label advises that the product may contain inactive ingredients, such as certain flavorings or colorings, that could potentially cause allergic reactions in sensitive individuals.

Q: Is the active ingredient an anti-inflammatory compound?

The active ingredient Benzocaine is classified as a local anesthetic and oral pain reliever. Its documented action is to interrupt nerve signals (numbing), and it is not classified as an anti-inflammatory compound.

How should Cepacol Extra Strength Cherry be stored and disposed of?

Storage and Handling

Official labeling requires Cēpacol Extra Strength Cherry lozenges to be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). It is mandatory to protect the product from humidity and to avoid exposure to excessive heat or moisture to maintain product stability.

Child Safety

As a crucial safety measure stated in the labeling, the product must always be stored out of the reach of children.

Official Disposal Procedures

Disposal of unused or expired lozenges is officially handled by utilizing a drug take-back program. If this option is not available, the product may be disposed of in household trash after being mixed with an undesirable substance, such as dirt or used coffee grounds, and placed in a sealed container. The medicine is not to be disposed of by flushing it down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cepacol Extra Strength Cherry found in:

A-Z Index: